Last updated: August 23, 2026
DIPRIVAN is the branded propofol injectable emulsion originally developed by Imperial Chemical Industries and later commercialized by AstraZeneca. Its commercial position has shifted from branded innovation to a mature hospital anesthetic market dominated by generic propofol. The product has no meaningful remaining exclusivity barrier in the United States, and AstraZeneca does not separately report DIPRIVAN revenue. Market performance is therefore driven by hospital purchasing contracts, manufacturing capacity, shortages, formulation reliability, and generic competition rather than brand pricing power.
What is DIPRIVAN and how is it used?
DIPRIVAN is a sterile injectable emulsion containing propofol, a short-acting intravenous sedative-hypnotic. It is approved for:
- Induction and maintenance of general anesthesia
- Initiation and maintenance of monitored anesthesia care sedation
- Initiation and maintenance of sedation in intubated, mechanically ventilated adults in intensive care units
The U.S. product is supplied primarily as a 10 mg/mL injectable emulsion in single-dose vials, prefilled syringes, and larger containers depending on the presentation and market. The formulation contains a lipid emulsion, including soybean oil and egg lecithin, which creates manufacturing, sterility, packaging, and handling requirements beyond those for a conventional small-molecule tablet.
The original U.S. application is NDA 019627. FDA approval occurred in 1989, establishing propofol as a major alternative to older intravenous anesthetics such as thiopental and methohexital (U.S. Food and Drug Administration [FDA], 2024a).
Who owns and markets DIPRIVAN?
AstraZeneca is the historical innovator and remains associated with the DIPRIVAN brand. The commercial rights structure has changed over time, particularly in the United States.
| Item |
Position |
| Active ingredient |
Propofol |
| Dosage form |
Intravenous injectable emulsion |
| Original developer |
Imperial Chemical Industries |
| Historical innovator |
Zeneca, later AstraZeneca |
| U.S. NDA |
019627 |
| Original U.S. approval |
1989 |
| Main commercial channel |
Hospitals, ambulatory surgery centers, intensive care units |
| Current market structure |
Brand plus multiple generic manufacturers |
| Primary competitors |
Generic propofol injectable emulsions |
| Biosimilar risk |
None, because propofol is a small molecule |
| Standalone DIPRIVAN revenue disclosure |
Not separately reported by AstraZeneca |
AstraZeneca has historically reported products such as DIPRIVAN within broader mature-product or established-product portfolios rather than publishing a separate annual revenue line. Public filings therefore do not support a verified current DIPRIVAN revenue series. The financial trajectory must be assessed through product maturity, generic penetration, and hospital utilization rather than reported brand sales.
How large is the propofol market?
Propofol is a high-volume hospital injectable, but public market estimates vary substantially because they may include different combinations of:
- Branded DIPRIVAN
- Generic propofol emulsions
- Different vial and syringe sizes
- Hospital tenders and direct purchasing
- Ambulatory surgery demand
- Intensive-care sedation
- International markets
- Contract-manufactured and private-label supply
The relevant commercial market is larger than the DIPRIVAN brand market. Generic propofol products are approved by FDA from multiple manufacturers, including Fresenius Kabi, Pfizer and other injectable-drug suppliers depending on the presentation and approval status. FDA’s Drug Shortages database has identified propofol supply disruptions during periods of elevated demand and manufacturing constraints (FDA, 2024b).
Propofol demand is relatively inelastic in the short term because it is embedded in operating-room and intensive-care protocols. Hospitals require reliable supply, but procurement departments can switch among therapeutically equivalent products when supply and contracts permit.
What is the financial trajectory for DIPRIVAN?
DIPRIVAN’s financial trajectory follows four phases.
Launch and adoption
The product gained adoption because it provided rapid onset, rapid recovery, and predictable titration. These characteristics supported use in general anesthesia, procedural sedation, and intensive-care settings.
Mature branded period
During the period when propofol had stronger brand differentiation, DIPRIVAN benefited from physician familiarity, hospital protocols, and manufacturing credibility. Its position was reinforced by the operational importance of injectable anesthesia products, where consistency and supply reliability matter.
Generic erosion
Once generic propofol products became widely available, the commercial economics changed. The active ingredient is a well-established small molecule, and generic manufacturers do not need to reproduce the DIPRIVAN brand. Hospital formularies and group purchasing organizations can use generic substitution and competitive tenders to reduce acquisition cost.
This typically produces:
- Lower branded unit volume
- Lower net pricing
- Reduced brand share
- Greater dependence on supply reliability
- Less value from historical brand recognition
Mature hospital commodity market
The current market is best characterized as a mature, low-growth injectable market. Volume follows procedure counts, intensive-care utilization, emergency medicine, and hospital capacity. Revenue growth for the brand is unlikely to come from price increases. Any positive trajectory is more likely to result from temporary shortages, distributor changes, geographic pockets of brand retention, or supply contracts.
AstraZeneca’s corporate reporting does not isolate DIPRIVAN sales, so a product-specific compound annual growth rate cannot be calculated from audited public disclosures (AstraZeneca, 2024).
What patents protect DIPRIVAN?
The original patent estate has expired. No active U.S. patent barrier comparable to those protecting a recently launched specialty drug is expected to prevent generic propofol entry.
Historical protection related to propofol and its pharmaceutical use included patents directed to the active compound, injectable formulations, and administration methods. The core commercial concept is now decades old. FDA’s Orange Book is the primary source for active patents and regulatory exclusivity associated with approved drug products. For DIPRIVAN, the relevant commercial conclusion is that the product has long operated in a genericized market (FDA, 2024c).
| IP category |
Commercial status |
| Propofol active ingredient |
Historical protection expired |
| Conventional injectable emulsion |
Historical protection expired or no longer commercially blocking |
| General anesthesia use |
No practical broad exclusivity barrier |
| ICU sedation use |
No practical broad exclusivity barrier |
| Device or container claims |
May affect individual products, but do not protect the propofol market broadly |
| Trade secrets |
Potential manufacturing value, not a substitute for market exclusivity |
What formulation patents protect propofol products?
Propofol is difficult to formulate because it is poorly water soluble and is supplied as a lipid emulsion. Product quality depends on emulsion stability, droplet-size control, sterility, preservative strategy, container closure, and compatibility with administration systems.
Formulation-related intellectual property can address:
- Lipid composition
- Emulsion stability
- Antimicrobial preservation
- Container and syringe configuration
- Manufacturing conditions
- Particle or droplet-size distribution
- Ready-to-use presentations
These rights may create commercial or regulatory friction for a particular copy product, but they do not restore broad exclusivity to DIPRIVAN. A generic manufacturer can pursue an abbreviated pathway with a formulation that satisfies FDA requirements without copying every commercial attribute of the branded product.
What is the FDA regulatory status of DIPRIVAN?
DIPRIVAN is an FDA-approved prescription injectable product. The primary regulatory pathway for competing propofol products is the abbreviated new drug application, or ANDA, provided the generic product meets applicable requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling.
FDA regulatory issues include:
- Sterility assurance
- Emulsion uniformity and stability
- Container closure integrity
- Manufacturing controls
- Particulate matter
- Microbial contamination risk
- Labeling for single-dose and multidose presentations
- Safe handling after opening
Propofol emulsions have a recognized risk of microbial growth if handled improperly. Product labeling therefore includes strict aseptic-use and storage requirements (FDA, 2024a).
When does DIPRIVAN lose exclusivity?
DIPRIVAN lost practical market exclusivity decades ago. The product received approval in 1989, and its commercial market has since included multiple generic propofol suppliers.
The key exclusivity milestones are:
| Milestone |
Approximate timing |
| U.S. approval |
1989 |
| Core small-molecule patent protection |
Expired years ago |
| Generic competition |
Established for many years |
| Current exclusivity position |
No meaningful broad U.S. market exclusivity |
| Paragraph IV exposure |
Historically relevant during generic entry; not a current brand-protection strategy |
Because propofol is not a biologic, biosimilar exclusivity does not apply. Competition proceeds through generic-drug regulation rather than the Biologics Price Competition and Innovation Act.
Which companies compete with DIPRIVAN?
The competitive field consists mainly of generic injectable-drug manufacturers rather than branded pharmaceutical innovators.
Major competitive groups
- Fresenius Kabi
- Pfizer and affiliated injectable businesses
- Hikma Pharmaceuticals
- Sagent Pharmaceuticals and related supply channels
- Other FDA-approved generic manufacturers
- Hospital and distributor private-label suppliers
The exact supplier mix differs by country, hospital system, vial size, and purchasing contract. Fresenius Kabi has particular relevance because of its broad injectable portfolio and historical association with propofol supply. Competition is based on price, allocation, regulatory compliance, product presentation, and continuity of supply.
Which companies have challenged DIPRIVAN patents?
Propofol generic entry occurred through the standard generic market rather than a current high-value patent dispute. Historical ANDA applicants may have used Paragraph IV certifications against listed patents where applicable, but public commercial importance now lies in generic supply rather than active patent litigation.
There is no known current patent litigation framework that materially protects DIPRIVAN’s U.S. market. A Paragraph IV challenge against an expired or commercially irrelevant patent would not create a meaningful barrier to generic entry.
What patent litigation affects DIPRIVAN?
No active litigation is publicly established as a material determinant of DIPRIVAN’s current commercial value. The principal risks are operational:
- Manufacturing interruptions
- FDA warning letters or recalls
- Shortage-related allocation
- Distributor substitution
- Hospital contract loss
- Product-quality events
- Changes in anesthesia practice
For a mature injectable, regulatory and supply-chain disputes can have greater economic impact than patent litigation. A manufacturing issue can reduce sales quickly, while a patent dispute is unlikely to restore long-term pricing power.
What generic launch risks exist for DIPRIVAN?
Generic launch risk remains high because:
- The active ingredient is well established.
- Generic propofol is already widely available.
- Hospital buyers are experienced with substitution.
- The product does not require a complex biologic comparability package.
- No broad active patent estate is known to block competition.
- Purchasing organizations have strong incentives to reduce injectable acquisition costs.
The main limitation on generic competition is not intellectual property. It is manufacturing complexity and supply reliability. Propofol is an emulsion, and sterile injectable production requires specialized facilities, validated processes, and sustained quality performance.
How strong is the DIPRIVAN patent estate?
The patent estate is commercially weak.
| Strength factor |
Assessment |
| Core molecule protection |
Expired |
| Broad formulation protection |
Expired or nonblocking |
| Method-of-use protection |
Narrow and nonblocking |
| Orange Book leverage |
Limited |
| Generic substitution risk |
High |
| Manufacturing know-how |
Potentially valuable |
| Litigation leverage |
Low |
| Long-term pricing protection |
Minimal |
The product may retain know-how value in emulsion manufacture, quality control, packaging, and supply management. That value is distinct from enforceable exclusivity.
What licensing deals affect DIPRIVAN?
The most relevant commercial arrangements have involved rights transfers, distribution, manufacturing, and supply rather than innovation licensing. AstraZeneca’s historical portfolio transactions and regional commercialization arrangements changed who marketed the product in particular territories.
No major current licensing transaction is publicly reported as a driver of DIPRIVAN’s financial outlook. Any value in a regional arrangement would depend on supply rights, hospital contracts, and manufacturing economics rather than patent duration.
What is the geographic coverage of DIPRIVAN?
DIPRIVAN has been marketed internationally, but brand presence varies by jurisdiction. Many countries use propofol supplied under generic or local brand names. The global market is therefore fragmented by:
- National drug procurement systems
- Hospital tender rules
- Local manufacturing
- Import requirements
- Reimbursement policy
- Brand substitution rules
- Regulatory approval of individual presentations
The United States remains commercially important because of its large procedural and hospital market, but generic competition is intense. European and emerging markets may show stronger local-brand participation and more tender-driven pricing.
What manufacturing and IP barriers remain?
The principal barriers are technical and regulatory rather than patent-based.
A manufacturer must control:
- Sterile production
- Emulsion droplet size
- Physical stability
- Preservative performance
- Fill volume and concentration
- Container compatibility
- Cold-chain or storage requirements where applicable
- Batch consistency
- Pharmacovigilance and recall readiness
These requirements can reduce the number of reliable suppliers, particularly during demand spikes. They do not, however, give DIPRIVAN durable monopoly economics.
How does DIPRIVAN compare with other intravenous anesthetics?
| Product |
Commercial position |
Key economic characteristic |
| DIPRIVAN |
Mature branded propofol |
Limited pricing power; brand recognition |
| Generic propofol |
Dominant competitive category |
Price and supply driven |
| Sevoflurane |
Inhaled anesthetic |
Competes by procedure and anesthesia preference |
| Desflurane |
Inhaled anesthetic |
Utilization affected by environmental and cost concerns |
| Etomidate |
Injectable induction agent |
Used selectively, with different clinical profile |
| Ketamine |
Injectable anesthetic and analgesic |
Broader use cases but different pharmacology |
| Midazolam |
Sedative |
Often used in procedural sedation, with slower recovery |
Propofol’s commercial advantage is its rapid onset and recovery profile. Its weakness for manufacturers is that the same clinical attributes support a large generic market rather than sustained brand differentiation.
What is the likely generic launch and revenue scenario?
The most likely scenario is continued generic dominance with stable or gradually growing total propofol volume and declining brand economics.
| Scenario |
Market effect |
DIPRIVAN implication |
| Stable procedure volumes |
Flat-to-low growth |
Mature, declining brand revenue |
| Hospital tender pressure |
Lower net prices |
Further share and margin erosion |
| Generic shortage |
Temporary share recovery |
Short-lived volume or pricing benefit |
| Manufacturing disruption |
Supply loss |
Revenue volatility and possible substitution |
| Growth in ambulatory surgery |
Higher propofol demand |
Benefits market volume more than brand |
| ICU demand surge |
Temporary volume increase |
Depends on allocation and inventory |
| New delivery technology |
Potential differentiation |
Requires new regulatory and IP investment |
The strongest commercial opportunity is likely in reliable generic supply, differentiated presentations, and contract manufacturing. The weakest opportunity is a conventional branded propofol strategy based on price premium.
Key Takeaways
- DIPRIVAN is a mature propofol injectable brand approved in the United States in 1989.
- Its core patents and practical market exclusivity expired long ago.
- Generic propofol is the main competitive force.
- AstraZeneca does not separately disclose DIPRIVAN revenue, preventing a verified product-level financial trend.
- Current economics depend on hospital tenders, manufacturing capacity, shortages, and supply reliability.
- Propofol formulation and sterile-manufacturing requirements remain technical barriers, but they do not create broad patent protection.
- Biosimilar risk is irrelevant because propofol is a small molecule.
- Current litigation and Paragraph IV activity do not appear to provide material protection for the brand.
- The most probable trajectory is stable total-market demand with continued erosion of branded revenue and pricing power.
FAQs
Is DIPRIVAN still patented?
No broad, commercially blocking patent protection is expected to remain for DIPRIVAN in the United States. The product has operated in a generic market for many years.
Is propofol a generic drug?
Yes. Propofol is available from multiple generic manufacturers in injectable emulsion presentations. DIPRIVAN is the original branded product.
Does AstraZeneca still report DIPRIVAN sales?
AstraZeneca does not separately identify DIPRIVAN revenue in its current public financial reporting. Sales are included within broader product or portfolio categories.
Can hospitals substitute generic propofol for DIPRIVAN?
Generally, hospitals can use FDA-approved generic propofol products under applicable pharmacy, formulary, and purchasing procedures. Substitution depends on institutional policy, product presentation, and supply availability.
Is DIPRIVAN at risk from biosimilars?
No. Biosimilar regulation applies to biologic products. DIPRIVAN contains propofol, a chemically synthesized small molecule, so competition occurs through generic-drug pathways.
References
-
AstraZeneca PLC. (2024). Annual report and Form 20-F 2023. https://www.astrazeneca.com/investor-relations/annual-reports.html
-
U.S. Food and Drug Administration. (2024a). DIPRIVAN (propofol) injectable emulsion prescribing information. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024b). Drug shortages: Propofol injection. https://www.accessdata.fda.gov/scripts/drugshortages/
-
U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
